Clinical trial · Interventional
Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients
Sipjeondaebo-tang for Alleviating Fatigue Measured by Brief Fatigue Inventory and EORTC-QLQ-C30, BR23 Score Change Among Patients With Breast Carcinoma Receiving Chemotherapy
NCT02858856CI-TRIAL-00029552unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot study that investigate efficacy and safety of Sipjeondaebo-tang on fatigue of patients with breast carcinoma receiving chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Carcinoma | Breast Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sipjeondaebo-tang | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- A group
- description
- Take Sipjeondaebo-tang on 0\~2 week, 3\~5 week of clinical trial period, total of 4 weeks
- interventionNames
- Drug: Sipjeondaebo-tang
- type
- EXPERIMENTAL
- label
- B group
- description
- Take Sipjeondaebo-tang on 6\~8 week, 9\~11 week of clinical trial period, total of 4 weeks
- interventionNames
- Drug: Sipjeondaebo-tang
Primary outcomes (2)
- measure
- Brief Fatigue Inventory change
- timeFrame
- 0-5 week
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * men and women aged over 18 years * patients who have histologically or cytologically confirmed breast tumor * patients who applicable AC(doxorubicin + cyclophosphamide) * ECOG score 0 to 2 Exclusion Criteria: * patient impossible to orally intake * patient with dementia, delirium and depression * patient suffering from diseases like chronic hepatitis B, C or hepatocirrhosis * severe liver disability (3-fold the normal high range value for ALT, AST) * patient who has diabetes not controlled by diet, hypertension, hyperthyroidism, * severe systemic disease * use of other investigational products within the past 30 days * hypersensitivity to investigational product * others who are judged not to be appropriate to study
References
Publications (1)
- DERIVEDCheon C, Kang S, Ko Y, Kim M, Jang BH, Shin YC, Ko SG. Sipjeondaebo-tang in patients with breast cancer with fatigue: a protocol for a pilot, randomised, double-blind, placebo-controlled, cross-over trial. BMJ Open. 2018 Jul 6;8(7):e021242. doi: 10.1136/bmjopen-2017-021242. PMID 29982213